"RANK Ligand" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A transmembrane protein belonging to the tumor necrosis factor superfamily that specifically binds RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B and OSTEOPROTEGERIN. It plays an important role in regulating OSTEOCLAST differentiation and activation.
| Descriptor ID |
D053245
|
| MeSH Number(s) |
D12.644.276.374.750.562 D12.776.467.374.750.562 D23.529.374.750.562
|
| Concept/Terms |
RANK Ligand- RANK Ligand
- OPGL Protein
- Osteoclast Differentiation Factor
- Differentiation Factor, Osteoclast
- Osteoprotegerin Ligand
- Receptor Activator of Nuclear Factor-kappa B Ligand
- Receptor Activator of Nuclear Factor kappa B Ligand
- Receptor Activator of Nuclear Factor-kappaB Ligand
- Receptor Activator of Nuclear Factor kappaB Ligand
- Tumor Necrosis Factor Ligand Superfamily Member 11
- TNF Superfamily, Member 11
- RANKL Protein
- Tumor Necrosis Factor-Related Activation-Induced Cytokine
- Tumor Necrosis Factor Related Activation Induced Cytokine
- CD254 Antigen
- Antigen, CD254
- TRANCE Protein
|
Below are MeSH descriptors whose meaning is more general than "RANK Ligand".
Below are MeSH descriptors whose meaning is more specific than "RANK Ligand".
This graph shows the total number of publications written about "RANK Ligand" by people in this website by year, and whether "RANK Ligand" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 0 | 2 | 2 |
| 2009 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2014 | 1 | 1 | 2 |
| 2015 | 1 | 1 | 2 |
| 2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "RANK Ligand" by people in Profiles.
-
Role of RANK-L as a potential inducer of ILC2-mediated type 2 inflammation in chronic rhinosinusitis with nasal polyps. Mucosal Immunol. 2020 01; 13(1):86-95.
-
Combination therapy with BMP-2 and a systemic RANKL inhibitor enhances bone healing in a mouse critical-sized femoral defect. Bone. 2016 Mar; 84:93-103.
-
Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease. Arthritis Rheumatol. 2015 Jan; 67(1):128-39.
-
BMP9 regulates cross-talk between breast cancer cells and bone marrow-derived mesenchymal stem cells. Cell Oncol (Dordr). 2014 Oct; 37(5):363-75.
-
Enhancement of an anti-tumor immune response by transient blockade of central T cell tolerance. J Exp Med. 2014 May 05; 211(5):761-8.
-
Mitogen- and stress-activated protein kinase 1 activates osteoclastogenesis in vitro and affects bone destruction in vivo. J Mol Med (Berl). 2013 Aug; 91(8):977-87.
-
IRF7-dependent IFN-ß production in response to RANKL promotes medullary thymic epithelial cell development. J Immunol. 2013 Apr 01; 190(7):3289-98.
-
Role of RANK-RANKL-OPG axis in cranial suture homeostasis. J Craniofac Surg. 2011 Mar; 22(2):699-705.
-
Binge alcohol-induced bone damage is accompanied by differential expression of bone remodeling-related genes in rat vertebral bone. Calcif Tissue Int. 2009 Jun; 84(6):474-84.
-
Coordinating development of medullary thymic epithelial cells. Immunity. 2008 Sep 19; 29(3):386-8.